“We are so honored to be recognized by our peers for this award,” says Dr. Lesley Rabach.

NEW YORK (PRWEB)
May 16, 2023

For patients seeking non-surgical medical treatment for dermatological needs or wanting to explore cosmetic surgery, LM Medical NYC offers the best of both worlds. As founders of the practice, Dr. Lesley Rabach, facial plastic surgeon, and Dr. Morgan Rabach, a dermatologist, provide the highest-quality medical, surgical and cosmetic care for patients. They are both proud to be featured as “Top Doctors” for 2023 by Castle Connolly in their medical fields. Physicians who receive this impressive award are among the very best in their specialties. The education, training, hospital appointments and disciplinary history of Dr. Lesley Rabach and Dr. Morgan Rabach were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com, as well as in a wide variety of partner publications, magazines and affiliate websites. The doctors who are listed in their books and directories were nominated by peers and put through an extensive evaluation process.

At LM Medical NYC, patients receive the benefit of access to two top physicians in their respective medical fields, all at one state-of-the-art facility. Dr. Lesley Rabach is an Ivy League trained expert facial plastic and reconstructive surgeon, and board certified in both facial plastic surgery and otolaryngology-head and neck surgery. Her surgical training included a fellowship sponsored by the American Academy of Facial Plastic Surgery and a residency and internship in Otolaryngology-Head and Neck Surgery at Yale New Haven Hospital. She received her Medical Degree from Drexel University College of Medicine and her undergraduate degree from Brown University. Her extensive education, training and experience have earned accolades in her field, and she has been published in various medical journals. Dr. Morgan Rabach has been nationally recognized for her many accomplishments in dermatology and aesthetics. In addition to her private practice, she is a clinical assistant professor of Dermatology at The Icahn School of Medicine at Mount Sinai Hospital. She graduated from Brown University with Honors in Biology, earned her medical degree from NYU- School of Medicine, completed her medical internship at Yale New Haven Hospital and she served as chief resident during her dermatology residency at SUNY Downstate Medical Center. Dr Morgan Rabach has received many top rankings in her field and has a substantial media presence in well-known beauty publications around the world.

“We are so honored to be recognized by our peers for this award,” says Dr. Lesley Rabach.

More about LM Medical NYC:

LM Medical NYC’s clinic is located at 33 Fifth Avenue #1B in New York, NY, and provides cutting-edge cosmetic surgery and skin care treatments As sisters and founders of the practice, Dr. Lesley Rabach and Dr. Morgan Rabach combine their expertise in facial plastic surgery and dermatology, to provide a customized approach to meet each patient’s personal needs. LM Medical NYC has created a comfortable, upscale atmosphere, providing many services, ranging from the latest in clinical dermatology treatments to non-invasive cosmetic injections and youthful makeovers with plastic surgery. For more information or to schedule a consultation or appointment, please call 212-770-2272, or visit http://www.lmmedicalnyc.com.

Share article on social media or email:

To be ranked as the nation’s top developer by Modern Healthcare’s Construction & Design Survey for 20 years is an incredible accomplishment that reflects the collective expertise and value that Hammes brings to our healthcare provider clients.

MILWAUKEE (PRWEB)
May 16, 2023

The Modern Healthcare 2023 Construction & Design Survey recognized Hammes as the nation’s No. 1 healthcare developer. This marks the 25th consecutive year in which Hammes was ranked as one of the top healthcare developers, with 20 of those years being in the No. 1 position.

The annual Modern Healthcare Construction & Design Survey, first published in 1980, ranks development firms based on the dollar volume of healthcare construction projects completed in the previous calendar year. Projects include outpatient and inpatient projects spanning new construction as well as expansions and renovations.

Last month, Hammes was also ranked as the No. 1 developer in the Revista 2023 Outpatient Healthcare Real Estate Development Report, which measures outpatient development activity. This is the first year the same company ranked as No. 1 in both surveys since the inception of the annual Revista report in 2017.

“To be ranked as the nation’s top developer by Modern Healthcare’s Construction & Design Survey for 20 years is an incredible accomplishment that reflects the collective expertise and value that Hammes brings to our healthcare provider clients,” said Nancy Connolly, President of Hammes Healthcare. “We are grateful to our incredible team members as well as our clients and industry partners who we have the privilege to work with on truly transformative healthcare projects.”

About Hammes

Founded in 1991, Hammes is a vertically integrated real estate solutions platform specializing in healthcare real estate strategy and planning, project management, development, investment, and property management. As a testament to our deep healthcare industry experience, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 25 consecutive years—including 20 years as No. 1— and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. http://www.hammes.com

Share article on social media or email:

A-Alpha Bio

“Our collaboration with the A-Alpha Bio team leverages their platform and expertise toward state-of-the-art computational models that will accelerate drug discovery.”

SEATTLE (PRWEB)
May 16, 2023

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, and Lawrence Livermore National Laboratory (LLNL), a federally funded research and development center, today announced their intention to collaborate to combat multiple pathogen families of concern. To enable this work, A-Alpha Bio has been awarded an additional $2.4M sub-contract from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in support of the Generative Unconstrained Intelligent Drug Engineering (GUIDE) Program, which the company will use to generate large-scale and quantitative protein-protein interaction (PPI) data and support LLNL’s advanced high-performance computational models for antibody discovery and development.

In support of DOD, over the past year, A-Alpha and LLNL have measured tens of millions of protein interactions between antibodies and coronavirus variants using A-Alpha Bio’s AlphaSeq platform. The experimental data has proven valuable for building and refining LLNL’s computational models for predicting antibody sequences that bind to current and possible future variants of concern. Beyond the pandemic, there is a well-recognized need to ensure preparation for other potential biological threats. Under the GUIDE program, A-Alpha and LLNL will focus their efforts to generate antibody-antigen binding data and train predictive Machine Learning (ML) models for multiple pathogen families prioritized by the DOD.

A-Alpha Bio’s AlphaSeq platform represents the first large-scale and quantitative approach for measuring protein-protein interactions. The AlphaSeq platform can simultaneously measure millions of interactions between antibodies and antigens to determine properties like affinity, specificity, cross-reactivity, and epitope engagement. These data are particularly valuable for training and validating ML models aimed at predicting desirable antibody sequences for therapeutic development. Under the new funding, the teams will work on 5 selected pathogen families that are considered biothreats.

Antibody libraries from LLNL and others will be synthesized and cloned into the AlphaSeq platform to measure all pairwise interactions between each antibody and a library of antigen variants. LLNL will use the binding data to train and refine ML models that learn the affinity landscape across antibody and antigen sequence space. Antibodies with desirable in silico binding profile predictions will be synthesized and tested in subsequent AlphaSeq assays for validation and refinement. Highly predictive ML models will enable computational design of antibodies against never before seen pathogen variants, reducing the response time for future biothreats.

“Based on our experience working with the LLNL team and the computational resources and knowhow that they bring, we are excited to tackle multiple pathogen families beyond COVID,” said Dr. David Younger, Co-Founder and CEO of A-Alpha Bio. “This expanded scope underscores the value of large-scale and high-quality antibody-antigen binding data for training ML models and the importance of rapid experimental iteration to test and refine those models.”

LLNL’s platform integrates world-class high-performance computing and simulation, machine learning, structural bioinformatics, and multi-objective optimization to perform in silico antibody and antigen design and optimization. Critical to these computational models is antibody-antigen binding data that can be experimentally determined using AlphaSeq.

“The AlphaSeq platform can rapidly measure millions of antigen-antibody binding affinities, providing data for our high-performance computational models and enabling accurate binding predictions,” said Daniel Faissol, Principal Investigator for AI-Driven Development of Biologic Countermeasures at LLNL. “Our collaboration with the A-Alpha Bio team leverages their platform and expertise toward state-of-the-art computational models that will accelerate drug discovery.”

About A-Alpha Bio

A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.

The company’s AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company’s AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.

A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington’s Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

About Lawrence Livermore National Laboratory

Founded in 1952, Lawrence Livermore National Laboratory provides solutions to our nation’s most important national security challenges through innovative science, engineering and technology. Lawrence Livermore National Laboratory is managed by Lawrence Livermore National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration.

About the JPEO-CBRND

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the Joint Force across combined Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. This contract was funded by the Joint Project Lead for CBRND Enabling Biotechnologies (JPL CBRND-EB) in collaboration with the Department of Energy (DOE) under agreement # A2210-021-089-033253. To learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.

Share article on social media or email:

“Nausea symptoms are felt everywhere – the mouth, throat, chest, stomach, or throughout your entire body,” explained Rich Ransom, President & CEO at Reliefband. “Our research shows that individuals suffering from nausea avoid social gatherings, certain foods, and outdoor activities.”

HORSHAM, Pa. (PRWEB)
May 16, 2023

Reliefband®, an innovator in wearable technology that prevents and treats nausea and vomiting, has released its First Annual State of Nausea study. According to the survey findings, nausea is epidemic in the United States, with 73% of Americans reporting that they suffer from nausea regularly. Of those who suffer from nausea, 76% stated that their symptoms prevent them from enjoying life to the fullest.

Released on National Stop Nausea Day, the study sheds light on the magnitude of the problem and its far-reaching consequences. 31% of Americans reported experiencing nausea every day, 26% at least once weekly, and 16% once each month. Making matters worse, more than half of the respondents (55%) indicated that they had yet to find an effective solution for their condition. This underscores previous research by Reliefband in 2020 that found sufferers often rely on home remedies, holistic techniques, over the counter and prescription medications, behavior modification, or just suffer with the condition doing nothing at all.

“Nausea is too often trivialized. The reality is that it ruins plans and leads to missed opportunities,” explained Rich Ransom, President, and CEO at Reliefband. “Nausea symptoms are felt everywhere – the mouth, throat, chest, stomach, or throughout your entire body. This robs sufferers of motivation, productivity, and sleep. It also hinders plans and life experiences. Everyday activities become more complicated, and our research shows that individuals suffering from nausea avoid social gatherings, certain foods, and outdoor activities such as boating, fishing, and skiing.”

The study revealed how nausea can affect daily life in many unpleasant ways. More than 18% of respondents reported that their nausea actively hindered their ability to travel, while some could not socialize (3.2%) or even work (2.9%). These findings highlight how nausea extends beyond mere inconvenience for a large majority of the U.S. population.

When describing the intensity of their nausea on a scale of 1 to 10 (10 being unbearable), “7” was the number used by most respondents to rate how overbearing their nausea is. 58% said their discomfort level was seven through 10 on the scale. This echoes earlier research conducted by Reliefband, in which more than half of nausea sufferers (54%) said they experienced moderate to severe symptoms.

Most nausea was reportedly caused by motion sickness: 49.4% of respondents attributed their symptoms to transport, including seasickness (26.0%), carsickness (11.9%), trainsickness (9.6%), and airsickness (1.9%). Other motion-related triggers mentioned by respondents included virtual-reality gaming (9.2%) and amusement park rides (1.6%).

Other common causes of nausea reported in the study included health and mental health issues such as morning sickness, anxiety, chemotherapy treatment, migraines, and post-operative effects. Concerning morning sickness, nausea, and vomiting affect up to 80% of pregnant women, according to a study published by the National Institutes of Health. Taking into account that 3.7 million babies were born in the U.S. in 2022, morning sickness affected nearly three million expectant mothers last year alone.

Reliefband’s First Annual State of Nausea study employed an online survey to collect data from 5,300 U.S. respondents. The survey was completed in December 2022 and consisted of a diverse group of consumers, with 82% of respondents evenly distributed between 25 and 65 years of age.

National Stop Nausea Day is observed every year in the U.S. on the third Tuesday in May. The purpose of the day is to give a voice to nausea sufferers, which affects millions of Americans daily. This day is intended to raise awareness of the causes of nausea, its pervasiveness among Americans, and to create a dialog on innovative treatment options. In observance of National Stop Nausea Day on May 16th, Reliefband’s entire line of anti-nausea wearables are $50 off when using promo code “STOP” at http://www.reliefband.com.

Reliefband is committed to addressing the urgent issue of nausea with wearable therapeutic technology that transforms how nausea and vomiting are managed. Reliefband devices use FDA-cleared, patented neuromodulation technology to target the underlying causes of nausea and provide fast, drug-free relief. Reliefband’s products gently stimulate the median nerve on the underside of the wrist, rebalancing the signals between the brain and the stomach. Reliefband wearables effectively reduce symptoms of nausea and vomiting due to motion sickness, morning sickness during pregnancy, chemotherapy, anxiety, hangovers, physician-diagnosed migraines, and as an adjunct to antiemetics in treating post-operative nausea.

About Reliefband

Reliefband is a world leader in neuromodulation and wearable technology. The company’s patented, clinically proven wearable solution quickly prevents and effectively treats nausea and vomiting. Its unique, FDA-cleared neuromodulation technology was originally developed for use in hospitals and alters nerve activity through targeted delivery of gentle pulses to the underside of the wrist to “turn off” feelings of nausea and vomiting. Reliefband is a drug-free alternative that eliminates the discomfort associated with nausea and vomiting. The Reliefband wearable solution has been an industry leader for more than 20 years and is available OTC, at Reliefband.com and Amazon.com. For more information, visit http://www.Reliefband.com.

Share article on social media or email:

The asthma & allergy friendly® Certification Program announces a new certification standard in response to increasing pollen counts and pollen allergies

“The new window-mounted pollen screen certification standard is an important step to promote accessible options to people with asthma and allergies,” shared Kenneth Mendez, CEO and president of AAFA.

WASHINGTON (PRWEB)
May 16, 2023

The asthma & allergy friendly® Certification Program, managed by Allergy Standards Ltd (ASL) and the Asthma and Allergy Foundation of America (AAFA), is excited to announce a new asthma & allergy friendly® certification standard for window-mounted pollen screens.

The new standard ensures that any pollen-blocking window screens that earn the asthma & allergy friendly®certification mark must pass rigorous scientific testing standards to prove that they:

• Can effectively block the passage of pollen
• Can be cleaned of captured pollen for lasting performance
• Have a low presence of allergenic chemicals and volatile organic compound (VOC) emissions

“Pollen seasons are getting more intense and longer due to climate change. Pollen is the most common source of seasonal allergies and can trigger allergic asthma,” shared Kenneth Mendez, CEO and president of AAFA. “Allergen avoidance in the home is an important part of asthma and allergy management plans – but many people do not have air conditioning to cool their homes when it’s hot. The new window-mounted pollen screen certification standard is an important step to promote accessible options to people with asthma and allergies.”

It is recommended that people with pollen allergies keep their windows closed during pollen season or at peak pollen times. However, pollen screens can be installed in window frames to help prevent pollen from entering the indoor environment from outdoors, enabling people with pollen allergies to open their windows and ventilate their indoor environment.

“Over 100 million people in the United States have an allergic disease – with 81 million people affected by allergic rhinitis caused by pollen allergy. It is prudent to have a certification standard that scientifically validates a pollen screen as being an effective filter,” said Dr. John McKeon, CEO of ASL. “These products fall between a building material and an interior furnishing, and since the asthma & allergy friendly® Certification Program has certification standards in both categories, we are well-placed to bring together elements from both in this new standard.”

The new window-mounted pollen screen certification standard involves a three-step testing process.

• First, the screens are tested for their ability to block the passage of pollen. Testing involves three types of pollen – one tree pollen, one grass pollen, and one weed pollen – to capture the major groups of pollens. The screens must effectively block all three types of pollen to receive certification.
• Second, the removal of pollen from the screen by cleaning is tested. To ensure lasting performance of a pollen screen, it must be possible to remove captured pollen to maintain ventilation while retaining performance.
• Last, the chemical make-up of the product is assessed for the presence of allergenic chemicals and emissions of VOCs to make sure they are below certification levels.

After undergoing and passing this strict testing process, manufacturers and retailers can now offer CERTIFIED asthma & allergy friendly® window-mounted pollen screens that provide an accessible and lower-cost option for people with pollen allergies.

###

About the asthma & allergy friendly® Certification Program

The asthma & allergy friendly® Certification Program is a unique, ground-breaking collaboration between the Asthma and Allergy Foundation of America and Allergy Standards Limited. This program helps people make informed purchases for a healthier home. The program tests household products against strict standards. Products passing these tests earn the CERTIFIED asthma & allergy friendly® mark. Certified products include air cleaners, bedding, cleaning products, flooring, paints, vacuum cleaners, washing machines, and more. Visit aafa.org/certified for more information.

Share article on social media or email:

During this webinar, attendees will see featured case studies from users of the Solentim ICON, an instrument that was specifically designed to meet the demands of the cell line development workflow.

TORONTO (PRWEB)
May 16, 2023

In cell line development today, the pressure to make decisions on best-performing clones earlier and shorten timelines continues to grow. One factor in the decision-making process is a cell line’s productivity, necessitating the measurement of titer.

Currently, titer measurements in cell line development are mostly performed using incumbent methods such as Octet and ELISA, which have their strengths but were not specifically developed for cell line development applications. The minimum sample volume requirements of these methods mean that titer measurements have often been neglected at the earlier cloning plate stage when 96 and 384 well plates are being used. Alternatively, samples have been diluted, leading to additional liquid handling steps and possible errors.

During this webinar, attendees will see featured case studies from users of the Solentim ICON, an instrument that was specifically designed to meet the demands of the cell line development workflow. ICON technology uses lower sample volumes for titer and viable cell density (VCD) measurements in higher density formats such as 384, 96 and 24 well plates. The case studies also show how faster titer measurements helped to allow clones to be excluded more rapidly, enabling decision-making earlier and shortening the cell line development process by days to weeks.

The user case studies also show how combining titer and confluence measurements from cell populations in the cloning plate gives a valuable new perspective regarding which clones turn out to perform best in shake flasks.

Join this webinar to see how to accelerate cell line development process timelines by leveraging early data points in the decision-making.

Join Kayla Bean, Principal Scientist, Cell Line Development, ACG Biologics; Paul Butler, Senior Product Leader, Advanced Instruments, LLC.; and Jenica Lee, Senior Research Associate, Wheeler Bio, for the live webinar on Tuesday, June 6, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Optimal Cell Line Development: Save Weeks AND Don’t Reject Your Highest Performing Clones.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email: